• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ispire Technology Inc. Reports Financial Results for the Fiscal Year 2024

    9/26/24 6:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email

    Record Revenue Year with Revenue Increasing 31.4% Year-Over-Year to $151.9 Million

    Gross Profit Increased 43.3% Year-Over-Year to $29.8 Million

    Submitted PMTA Application in September 2024 Planning to Re-enter US ENDS Market

    LOS ANGELES, Sept. 26, 2024 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal year 2024, which ended on June 30, 2024, and will file its annual report on Form 10-K with the U.S. Securities and Exchange Commission (the "SEC") on September 26, 2024.

    Fiscal Year 2024 Financial Results

    • Revenue increased 31.4% to $151.9 million as compared to $115.6 million in the 2023 fiscal year.
    • Gross profit increased 43.3% to $29.8 million compared to $20.8 million in the 2023 fiscal year.
    • Gross margin increased to 19.6% as compared to 18.0% in the 2023 fiscal year;
    • Total operating expenses increased 73.0% to $43.7 million as compared to $25.3 million in the 2023 fiscal year.
    • Net loss of ($14.8) million as compared to net loss of ($6.0) million in the 2023 fiscal year.

    Michael Wang, Co-Chief Executive Officer of Ispire, commented,

    • "Fiscal year 2024 was a foundational year for Ispire, marked by record revenue and substantial margin expansion while strategically positioning us for faster growth in our global nicotine business and intentionally focusing our cannabis vaping hardware on high quality multi-state operator (MSO) customers.



    • We continued to increase our revenue as we forged strategic long term partnerships with industry leaders such as Acreage Holdings, Hidden Hills Club, Dank Pack, and BRKFST, a brand produced and sold under a license arrangement with international singer and songwriter Burna Boy. These collaborations helped to expand our market presence, increase distribution channels, and solidify our global operating infrastructure.



    • We enhanced our manufacturing capabilities with the opening of a state-of-the-art 31,000 sq. ft. facility in Malaysia earlier this year as we aim to capitalize on the international nicotine market while driving our costs down and increasing profitability. We expect to continue to realize incremental margin improvements with this facility as production throughput increases.



    • We successfully closed on a $12.3 million public offering this past spring which helped strengthen our financial standing and has positioned us to expand on future international growth opportunities in both the nicotine and cannabis sectors.



    • Additionally, we bolstered our senior leadership team with key appointments: Jim McCormick as Chief Financial Officer, John Patterson as Senior Vice President of International Nicotine, and Dennis Lider as Senior Vice President of Cannabis Vaping Hardware Sales.



    • While we are excited by our results, we are even more optimistic about our path forward. We continue to work towards an industry-leading point-of-use age-verification solution for vapor devices as well as continue to introduce cutting-edge technology across the U.S. e-cigarette market.



    • We recently submitted our first PMTA application in four years for a disposable ENDS product with four flavors. This is an important milestone for the Company, as we aim to re-enter the U.S. ENDS market. While we maintain our focus on innovation to drive topline growth, we are equally committed to achieving sustainable margin improvements. At the same time, we are taking steps to limit underage access to vaping products in line with the Company's values which focus on responsible marketing to adult consumers.



    • We believe these initiatives have collectively positioned us to capitalize on future market opportunities while delivering long-term value to our stakeholders."

    Jim McCormick, Chief Financial Officer of Ispire, stated, "Our fiscal year 2024 results reflect our ability to successfully execute across our business segments, with a strategic focus on the international nicotine market as our primary revenue, margin, and future profit driver given its significant market size.

    We recognize we have taken calculated risks with our cannabis investments in the US over the course of 2024.  We have expanded our customer base as well as sales to existing customers while improving our gross margins as the year progressed.  While we have made significant gains in market share, we also experienced challenges with slow-paying customers related to the systemic cash demands placed on the US cannabis industry. 

    Much of this can be linked to the cannabis specific 280E requirements, perpetuated by the lack of cannabis rescheduling from a Schedule I to a Schedule III controlled substance.  In addition, ongoing industry conditions as well as the current regulatory and taxation environment are placing pressure on our customer's cash flow and ability to pay us in a timely manner.

    Despite these challenges, we remain very confident in our growth trajectory.  Our strategic realignment positions the Company to drive growth initiatives in both the nicotine and cannabis sectors, with a renewed focus on quality investments. Furthermore, we are continuing to drive costs down as we expand our utilization of our Malaysian production facility. This facility significantly bolsters our manufacturing capabilities, while providing operational efficiency and reducing our product costs."

    Financial Results for the Fiscal Year Ended June 30, 2024

    For the fiscal year ended June 30, 2024, Ispire reported revenue of $151.9 million compared to $115.6 million during the same period last year, an increase of 31.4%. The increase in revenue was primarily attributable to the combined effect of increases in product sales in the United States of $21.5 million from $41.6 million for the year ended June 30, 2023 to $63.1 million for the year ended June 30, 2024, increases in sales of vaping products in Europe of $6.5 million from $58.8 million for the year ended June 30, 2023 to $65.3 million for the year ended June 30, 2024, and increases in sales of vaping products in other markets of $5.7 million from $0.3 million for the year ended June 30, 2023 to $6.0 million for the year ended June 30, 2024, mainly contributed by increase in sales to South Africa of $5.4 million.

    Gross profit for the fiscal year ended June 30, 2024, was $29.8 million compared to $20.8 million for the same period in fiscal year 2023. Over this same period, our gross margin grew to 19.6%, from 18.0%. The increase in gross profit and gross margin during the fiscal year 2024 was primarily due to a change in product mix focusing on higher margin products, higher sales volume leading to improved economies of scale, and the benefits derived from production in the Company's Malaysia facility.

    Total operating expenses for the fiscal year ended June 30, 2024 were $43.7 million as compared to $25.3 million in the same period in fiscal year 2023. This increase was primarily due to expenses to support the expanded business footprint in the areas of payroll and contract wages, sales and marketing, professional fees as well as increased stock-based compensation.

    For the fiscal year ended June 30, 2024, net loss was ($14.8) million or ($0.27) per share, compared to a net loss of ($6.0) million, or ($0.12) per share for fiscal year 2023.

    As of June 30, 2024, Ispire had $35.1 million in cash and cash equivalents and working capital of $16.6 million.

    Conference Call

    The Company will conduct a conference call at 8:00 am Eastern Time on Thursday, September 26, 2024, to discuss the results. Ispire management will host the conference call, followed by a question-and-answer period.

    Please call the conference call dial-in 5-10 minutes prior to the start time and ask for the "Ispire Technology Call." An operator will register your name and organization.

    • Date: Thursday, September 26, 2024
    • Time: 8:00 am ET
    • Dial-In Numbers: United States 877-451-6152 or International +1 201-389-0879

    This conference call will be broadcast live on the Internet and can be accessed by all interested parties at https://viavid.webcasts.com/starthere.jsp?ei=1683501&tp_key=2e98778e22

    Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

    A playback will be available from 11:00 am ET on September 26, 2024 through October 10, 2024. To listen, please dial 844-512-2921 or +1 412-317-6671. Use the passcode 13748321 to access the replay.

    About Ispire Technology Inc.

    Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 200 patents received or filed globally. Ispire's tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company's cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Canada, Germany and South Africa. For more information, visit www.ispiretechnology.com or follow Ispire on  Instagram , LinkedIn, Facebook, TwitterInstagram, LinkedIn, Facebook, Twitter and YouTube. Any information contained on, or that can be accessed through, the Company's website, any other website or any social media, is not a part of this press release.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company's joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the "Joint Venture") may be successful in achieving its goals as currently contemplated, with different terms, or at all, the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices, the Company's ability to collect its accounts receivable in a timely manner, the Company's business strategies, the ability of the Company to market to the Ispire ONE™, Ispire ONE™'s success if meeting its goals, the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe, and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2023 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONSOLIDATED BALANCE SHEETS

    (In $USD, except share and per share data)







    June 30







    2023





    2024







    (to be restated 

    on Form 10-K

    for fiscal

    year 2024)









    Assets













    Current assets:













    Cash



    $

    40,300,573





    $

    35,071,294



    Accounts receivable, net





    24,526,262







    59,734,765



    Inventories, net





    7,472,108







    6,365,394



    Prepaid expenses and other current assets





    3,378,617







    1,400,152



    Investment – other





    9,133,707







    -



    Total current assets





    84,811,267







    102,571,605



    Other assets:

















    Property, plant and equipment, net





    1,088,131







    2,582,457



    Intangible assets, net





    -







    1,375,666



    Right-of-use assets – operating leases





    4,253,732







    3,579,140



    Other investment





    -







    2,000,000



    Equity method investment





    -







    10,248,048



    Other non-current assets





    242,614







    284,050



    Total other assets





    5,584,477







    20,069,361



    Total assets



    $

    90,395,744





    $

    122,640,966



    Liabilities and stockholders' equity

















    Current liabilities

















    Accounts payable



    $

    1,274,391





    $

    3,779,723



    Accounts payable – related party





    51,698,588







    67,046,472



    Contract liabilities





    988,556







    2,218,166



    Accrued liabilities and other payables





    281,361







    11,738,339



    Due to a related party





    710,910







    -



    Income tax payable





    63,853







    -



    Operating lease liabilities – current portion





    837,100







    1,207,832



    Total current liabilities





    55,854,759







    85,990,532





















    Other liabilities:

















    Operating lease liabilities – net of current portion





    3,071,075







    2,194,094



    Total liabilities





    58,925,834







    88,184,626





















    Commitments and contingencies



































    Stockholders' equity:

















    Common stock, par value $0.0001 per share; 140,000,000 shares authorized;

    54,222,420 and 56,470,636 shares issued and outstanding as of June 30, 2023 and

    June 30, 2024





    5,422







    5,647



    Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no

    shares issued at June 30, 2023 and June 30, 2024





    -







    -



    Additional paid-in capital





    25,685,475







    43,217,391



    Retained earnings (accumulated deficit)





    5,942,781







    (8,825,041)



    Accumulated other comprehensive (loss) income





    (163,768)







    58,343



    Total stockholders' equity





    31,469,910







    34,456,340



    Total liabilities and stockholders' equity



    $

    90,395,744





    $

    122,640,966



     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND

    COMPREHENSIVE LOSS

    (In $USD, except share and per share data)





    Years ended June 30,







    2023





    2024







    (to be restated

    on Form 10-K

    for fiscal

    year 2024)









    Revenue



    $

    115,605,536





    $

    151,908,691



    Cost of revenue





    94,828,472







    122,126,245



    Gross profit





    20,777,064







    29,782,446



    Operating expenses:

















    Sales and marketing expenses





    4,416,220







    6,608,724



    General and administrative expenses





    20,835,001







    37,067,861



    Total operating expenses





    25,251,221







    43,676,585



    Loss from operations





    (4,474,157)







    (13,894,139)



    Other income (expense):

















    Interest income, net





    195,209







    350,022



    Exchange loss, net





    (324,225)







    (70,293)



    Other (expense) income, net





    (155,150)







    128,634



    Total other (expense) income, net





    (284,166)







    408,363



    Loss before income taxes





    (4,758,323)







    (13,485,776)



    Income taxes – current





    (1,245,303)







    (1,282,046)



    Net loss



    $

    (6,003,626)





    $

    (14,767,822)



    Other comprehensive loss

















    Foreign currency translation adjustments                                                              





    20,896







    222,111



    Comprehensive loss





    (5,982,730)







    (14,545,711)



    Net loss per share

















    Basic and diluted



    $

    (0.12)





    $

    (0.27)



    Weighted average shares outstanding:

















    Basic and diluted





    50,725,814







    54,812,900



     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In $USD, except share and per share data)







    Years ended June 30,







    2023





    2024







    (to be restated

    on Form 10-K

    for fiscal

    year 2024)









    Net loss



    $

    (6,003,626)





    $

    (14,767,822)



    Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

















    Depreciation and amortization





    46,662







    505,653



    Credit loss expenses





    3,332,825







    6,015,752



    Right-of-use assets amortization





    1,030,104







    1,211,899



    Stock-based compensation expenses





    —







    6,380,282



    Inventory impairment





    —







    205,594



    Loss from equity method investment





    —







    117,905



    Changes in operating assets and liabilities:

















    Accounts receivable





    (19,579,339)







    (41,299,642)



    Inventories





    7,108,449







    901,120



    Prepaid expenses and other current assets





    (2,598,746)







    1,937,029



    Accounts payable and accounts payable – related party





    10,574,989







    17,891,667



    Contract liabilities





    (690,637)







    1,248,687



    Accrued liabilities and other payables





    168,179







    2,456,979



    Operating lease liabilities





    (1,427,398)







    (1,043,556)



    Income tax payable





    (417,260)







    (63,853)



    Net cash used in operating activities





    (8,455,798)







    (18,302,306)





















    Cash flows from investing activities:

















    Purchase of property, plant and equipment





    (1,020,768)







    (1,969,961)



    Acquisition of intangible assets





    —







    (1,173,302)



    Purchase of short term investment





    (9,133,707)







    —



    Maturity of short term investment





    —







    9,133,707



    Acquisition of other investment













    (2,000,000)



    Acquisition of equity method investment





    —







    (1,000,000)



    Net cash (used in) provided by investing activities





    (10,154,475)







    2,990,444





















    Cash flows from financing activities:

















    Net proceeds from initial public offering





    21,735,000







    —



    Payment of initial public offering costs





    (3,475,172)







    —



    Proceeds from equity offerings





    7,969,221







    12,300,000



    Issuance costs of equity offerings





    (543,153)







    (1,514,094)



    Payment made for dividends





    (3,362,639)







    —



    Repayments of advances from a related party





    (37,893,062)







    (703,323)



    Net cash (used in) provided by financing activities





    (15,569,805)







    10,082,583





















    Net decrease in cash





    (34,180,078)







    (5,229,279)



    Cash – beginning of period





    74,480,651







    40,300,573



    Cash – end of period



    $

    40,300,573





    $

    35,071,294



    Supplemental non-cash investing and financing activities

















    Leased assets obtained in exchange for operating lease liabilities



    $

    4,988,032





    $

    537,307



    Unpaid equity method investment in accrued liabilities and other payables



    $

    —





    $

    9,000,000



    Warrants issued in connection with equity method investment



    $

    —





    $

    365,954



    Unpaid intangible assets in accrued liabilities and other payables



    $

    —





    $

    232,382



    Supplemental disclosures

















    Cash paid for income taxes



    $

    1,663,240





    $

    1,355,110



    Cash paid for interest



    $

    587





    $

    15,229



     

    For more information, kindly contact:

    IR Contacts:

    Investor Relations

    Sherry Zheng

    718-213-7386

    [email protected]

    KCSA Strategic Communications

    Phil Carlson

    212-896-1233

    [email protected]

    PR Contact:

    Ellen Mellody

    570-209-2947

    [email protected]

     

    Cision View original content:https://www.prnewswire.com/news-releases/ispire-technology-inc-reports-financial-results-for-the-fiscal-year-2024-302259490.html

    SOURCE Ispire Technology Inc.

    Get the next $ISPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    2/6/26 4:30:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    11/6/25 4:31:10 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Ispire Technology Inc.

    10-K - Ispire Technology Inc. (0001948455) (Filer)

    9/15/25 4:06:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire-Backed IKE Tech Invited to Participate in FDA Roundtable on PMTA Submissions

    Invitation-Only Forum Underscores FDA Recognition of IKE Tech as a Key Stakeholder and Highlights the Strategic Role of Age-Gating Technology in the Future of ENDS Regulation and Compliance LOS ANGELES, Feb. 4, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced that IKE Tech LLC ("IKE Tech" or "IKE"), a joint venture that includes Ispire as a founding partner, has been invited by the U.S. Food and Drug Administration (FDA) to participate in its Roundtable Discussion with Small ENDS Manufacturers on Premarket Tobacco Product Application (PMTA) Submissions.

    2/4/26 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $ISPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Wang Michael Xue bought $11,959 worth of shares (5,000 units at $2.39), increasing direct ownership by 1% to 466,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/2/26 4:58:37 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Co-Chief Executive Officer Wang Michael Xue bought $18,529 worth of shares (8,000 units at $2.32), increasing direct ownership by 2% to 461,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/26/26 4:27:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Wang Michael Xue bought $11,959 worth of shares (5,000 units at $2.39), increasing direct ownership by 1% to 466,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/2/26 4:58:37 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Co-Chief Executive Officer Wang Michael Xue bought $18,529 worth of shares (8,000 units at $2.32), increasing direct ownership by 2% to 461,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/26/26 4:27:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    CLO and Secretary Pryzbyla Steven P. sold $29,592 worth of shares (9,000 units at $3.29), decreasing direct ownership by 2% to 390,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/17/26 5:53:18 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Ispire Technology with a new price target

    ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

    5/20/24 7:18:59 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Financials

    Live finance-specific insights

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Second Quarter 2026 Earnings Conference Call

    LOS ANGELES, Feb. 3, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Friday, February 6, 2026, to discuss the Company's financial results for its fiscal second quarter ended December 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Friday, February 6, 2026Time: 8:00 am ETDial-In Number

    2/3/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal First Quarter 2026 Earnings Conference Call

    LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, November 6, 2025, to discuss the Company's financial results for its fiscal first quarter ended September 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Thursday, November 6, 2025Time: 8:00 am ETDial-In Nu

    11/4/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Leadership Updates

    Live Leadership Updates

    View All

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ispire Technology Inc.

    SC 13G - Ispire Technology Inc. (0001948455) (Subject)

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care